Intubation and Ventilation amid the COVID-19 Outbr
Post# of 153875
(Total Views: 852)
Posted On: 04/01/2020 8:17:08 AM
Intubation and Ventilation amid the COVID-19 Outbreak: Wuhan’s Experience
Reference to today's PR and some data behind the urgency to prove the efficacy of Leronlimab in severe patients and especially those intubated, I share the below (very sobering and prayers for continued success):
A friend in the field pointed me to this article in ANESTHESIOLOGY and it makes an attempt to estimate patient survival once intubated based upon Wuhan estimates.
https://anesthesiology.pubs.asahq.org/article...id=2763453
"...Currently, we do not have data detailing the total number of patients with COVID-19 who received intubation and invasive ventilation or details about the outcomes associated with and after these invasive interventions. Nonetheless, we can attempt to estimate this based on the available data. As of February 29, 2020, a total of 2,870 patients with confirmed COVID-19 have died (http://www.nhc.gov.cn/; accessed March 1, 2020). It is assumed that all of these patients died in ICUs, as most, if not all, of them should have been admitted to the ICU before their death. We estimate that, if using a mortality rate of 50% among patients who were admitted to the ICU, a total of 5,740 patients would have been admitted to the ICU (2,870 × 2 = 5,740) as of February 29, 2020. One recent report showed a mortality rate of 61.5% in patients who were admitted to the ICU.3 The other report showed a mortality rate of 49% among critically ill patients.8 We used a mortality rate of 50% in our estimate. Based on the data reporting an invasive ventilation rate of approximately 45% in patients who were admitted to the ICU,3,4 we estimate that approximately 2,583 patients with COVID-19 received intubation and invasive ventilation, accounting for approximately 3.2% (2,583 of 79,824) of all confirmed COVID-19 cases, as of February 29, 2020, in mainland China..."
Reference to today's PR and some data behind the urgency to prove the efficacy of Leronlimab in severe patients and especially those intubated, I share the below (very sobering and prayers for continued success):
A friend in the field pointed me to this article in ANESTHESIOLOGY and it makes an attempt to estimate patient survival once intubated based upon Wuhan estimates.
https://anesthesiology.pubs.asahq.org/article...id=2763453
"...Currently, we do not have data detailing the total number of patients with COVID-19 who received intubation and invasive ventilation or details about the outcomes associated with and after these invasive interventions. Nonetheless, we can attempt to estimate this based on the available data. As of February 29, 2020, a total of 2,870 patients with confirmed COVID-19 have died (http://www.nhc.gov.cn/; accessed March 1, 2020). It is assumed that all of these patients died in ICUs, as most, if not all, of them should have been admitted to the ICU before their death. We estimate that, if using a mortality rate of 50% among patients who were admitted to the ICU, a total of 5,740 patients would have been admitted to the ICU (2,870 × 2 = 5,740) as of February 29, 2020. One recent report showed a mortality rate of 61.5% in patients who were admitted to the ICU.3 The other report showed a mortality rate of 49% among critically ill patients.8 We used a mortality rate of 50% in our estimate. Based on the data reporting an invasive ventilation rate of approximately 45% in patients who were admitted to the ICU,3,4 we estimate that approximately 2,583 patients with COVID-19 received intubation and invasive ventilation, accounting for approximately 3.2% (2,583 of 79,824) of all confirmed COVID-19 cases, as of February 29, 2020, in mainland China..."
(4)
(0)